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 Background At the time of the initial analysis of overall survival (OS) for the Comparison of Faslodex in Recurrent or Metastatic 
Breast Cancer (CONFIRM) randomized, double-blind, phase III trial, approximately 50% of patients had died. 
A final analysis of OS was subsequently planned for when 75% of patients had died.
 Methods Patients were randomly assigned 1:1 to fulvestrant 500 mg administered as two 5-mL intramuscular injections on 
days 0, 14, and 28 and every 28 (±3) days thereafter or fulvestrant 250 mg administered as two 5-mL intramuscular 
injections (one fulvestrant and one placebo [identical in appearance to study drug]) on days 0, 14 (two placebo 
injections only), and 28 and every 28 (±3) days thereafter. OS was analyzed using an unadjusted log-rank test. No 
adjustments were made for multiplicity. Serious adverse events (SAEs) and best response to subsequent therapy 
were also reported. All statistical tests were two-sided.
 Results In total, 736 women (median age = 61.0 years) were randomly assigned to fulvestrant 500 mg (n = 362) or 250 mg 
(n = 374). At the final survival analysis, 554 of 736 (75.3%) patients had died. Median OS was 26.4 months for 
fulvestrant 500 mg and 22.3 months for 250 mg (hazard ratio = 0.81; 95% confidence interval = 0.69–0.96; nominal 
P = .02). There were no clinically important differences in SAE profiles between the treatment groups; no cluster-
ing of SAEs could be detected in either treatment group. Type of first subsequent therapy and objective responses 
to first subsequent therapy were well balanced between the two treatment groups.
 Conclusions In patients with locally advanced or metastatic estrogen receptor–positive breast cancer, fulvestrant 500 mg is 
associated with a 19% reduction in risk of death and a 4.1-month difference in median OS compared with fulves-
trant 250 mg. Fulvestrant 500 mg was well tolerated, and no new safety concerns were identified.
  J Natl Cancer Inst;2014;106:1–7 
Fulvestrant is a pure estrogen receptor (ER) antagonist devoid of 
the agonistic properties displayed by tamoxifen in some tissues 
(1–4). After phase III studies, which demonstrated similar efficacy 
and an acceptable safety profile for fulvestrant 250 mg compared 
with anastrozole (1,5), fulvestrant 250 mg was approved as treat-
ment in postmenopausal women with advanced hormone recep-
tor–positive breast cancer that had progressed or recurred after 
prior antiestrogen therapy. However, previous preoperative stud-
ies showed that short-term exposure to fulvestrant was associated 
with a dose-dependent reduction in the levels of ER, progesterone 
receptor, and the cell proliferation–related antigen Ki67 (6,7) for 
fulvestrant doses up to 250 mg. Other phase I and phase III stud-
ies also suggested a dose–response effect for fulvestrant (1,5,8).
The phase III Comparison of Faslodex in Recurrent or Metastatic 
Breast Cancer (CONFIRM) trial compared the then-approved dose 
and dosing schedule of fulvestrant (250 mg every 28 days) with a 
higher-dose regimen (500 mg every 28  days plus an additional 
500 mg on day 14 of the first month only) in postmenopausal women 
with locally advanced or metastatic ER-positive breast cancer that 
had recurred or progressed after prior endocrine therapy. The ini-
tial results showed that fulvestrant 500 mg was associated with a 
statistically significant increase in progression-free survival (PFS) 
without increased toxicity, therefore corresponding to a clinically 
meaningful improvement in benefit vs risk compared with fulves-
trant 250 mg (9). Based on these data, the 500-mg dose of fulves-
trant is now the approved dose in the European Union (approved in 
March 2010), United States (approved in September 2010), Japan 
(approved in November 2011), and other countries worldwide.
In the CONFIRM study, the assessment of the therapeutic effi-
cacy of both doses of fulvestrant was evaluated by several secondary 
outcome measures, including overall survival (OS). At the time of 
the initial analysis, approximately 50% of patients had died. After 
the reporting of the 50% survival data, which showed a trend in 
favor of 500 mg over 250 mg, it was agreed to perform a final sur-
vival analysis after 75% of patients had died. Here we report the 
results of this final OS analysis.
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Methods
Study Design and Patients
The CONFIRM study design, including eligibility criteria, exclu-
sion criteria, and the calculation of sample size, has been described 
in detail elsewhere (9). Briefly, CONFIRM was a randomized, 
phase III, double-blind trial that evaluated two different doses 
of fulvestrant (500 mg vs 250 mg) in postmenopausal patients 
who had either locally advanced or metastatic ER-positive breast 
cancer (ClinicalTrials.gov identifier: NCT00099437; http://
www.clinicaltrials.gov/ct2/show/NCT00099437). The primary 
study endpoint was PFS (the time elapsing between the date of 
randomization and the date of earliest evidence of objective dis-
ease progression or death from any cause). Secondary endpoints 
included objective response rate, clinical benefit rate, duration of 
response, duration of clinical benefit, OS, tolerability, and quality 
of life (9).
After initial analysis, all patients, regardless of whether they 
were still receiving randomized treatment, entered a survival fol-
low-up phase. Patients remaining on randomized treatment during 
this follow-up phase continued on blinded randomized treatment 
until progression and were assessed for serious adverse events 
(SAEs) and survival status. Patients who had discontinued rand-
omized treatment were assessed for their survival status and best 
response to their first subsequent systemic breast cancer therapy 
received after treatment discontinuation.
Ethics
The study was performed in accordance with the Declaration 
of Helsinki, consistent with International Conference on 
Harmonisation/Good Clinical Practice requirements. All patients 
gave written informed consent before study entry, and the study 
protocol was approved by the institutional review board of each 
participating institution.
Randomization and Masking
Patients were randomly assigned to treatment in balanced blocks 
using a computer-generated randomization schedule; all study per-
sonnel were blinded to randomized treatment. Eligible patients were 
randomly assigned 1:1 to either fulvestrant 500 mg administered as 
two 5-mL intramuscular injections on days 0, 14, and 28 and every 
28 (± 3) days thereafter or fulvestrant 250 mg administered as two 
5-mL intramuscular injections (one fulvestrant and one placebo 
[identical in appearance to study drug]) on days 0, 14 (two placebo 
injections only), and 28, and every 28 (± 3) days thereafter (9).
Fulvestrant was supplied in the form of a single dose in a pre-
filled syringe. Each active prefilled syringe contained 250 mg of 
fulvestrant at a concentration of 50 mg/mL in a volume of 5 mL, 
designated fulvestrant 5% weight/volume injection. The placebo 
prefilled syringe was identical to the active prefilled syringe and 
also had a volume of 5 mL.
Survival analysis
OS was defined as the number of days from randomization to death 
from any cause. Patients who died after the data cutoff or who were 
known to be alive after the data cutoff were right-censored at the 
date of the data cutoff. Patients who were last known to be alive 
before the data cutoff or who were lost to follow-up before the 
data cutoff were right-censored at the date they were last known 
to be alive.
After the initial analysis, patients on fulvestrant 250 mg were 
permitted to switch to 500 mg before entering the survival follow-
up phase. Irrespective of whether they were still receiving rand-
omized treatment, all patients in the follow-up phase continued to 
have their survival status monitored every 12 ± 2 weeks until cutoff 
for the final 75% OS analysis (October 31, 2011).
Best Response to First Subsequent Therapy
Details of the first subsequent systemic breast cancer therapy 
received after discontinuation of randomized treatment, and of the 
best response (complete response, partial response, stable disease, 
progressive disease, not evaluable) to this therapy were collected.
Tolerability
SAEs were reported to the Patient Safety Database and collated 
during the survival follow-up phase for those patients still receiving 
randomized treatment.
Statistical Analysis
OS was first analyzed in 2009, in parallel with the primary analysis 
of PFS, after the proportion of reported deaths exceeded 50% of 
the total number of patients randomized across the two treatment 
groups. The analysis was performed using an unadjusted log-rank 
test. An additional exploratory analysis, which used a Cox propor-
tional hazards model adjusting for six predefined covariables (age at 
baseline, response to last endocrine therapy received before fulves-
trant, receptor status at diagnosis, visceral involvement at baseline, 
last therapy before fulvestrant, and measurable disease at baseline) 
was also performed to assess the robustness of the unadjusted OS 
result.
An updated analysis is presented here of more mature survival 
data, performed after the proportion of reported deaths exceeded 
75% of the total number of patients randomized across the two 
treatment groups. The data were analyzed using log-rank statistics, 
confirmed by Cox proportional hazards model, and summarized 
by the method of Kaplan–Meier. P values presented are nominal 
without adjustment for multiplicity, and no alpha was retained for 
this analysis (the 5% error was used at the initial OS analysis). All 
statistical tests were two-sided.
For SAEs, summaries and analyses were prepared according to 
the treatment actually received.
results
Patients
In total, 736 women (median age  =  61.0  years) were randomly 
assigned between February 2005 and August 2007 from 128 cent-
ers in 17 countries (Belgium, Brazil, Chile, Colombia, Czech 
Republic, Hungary, India, Italy, Malta, Mexico, Poland, Russia, 
Slovakia, Spain, the United States, Ukraine, and Venezuela) (ful-
vestrant 500 mg: n = 362; fulvestrant 250 mg: n = 374) (Figure 1). 
Baseline patient and tumor characteristics, reported previously, 
were comparable between the treatment groups (9). At the time 
of the final analysis, 63 patients (8.6%) were lost to follow-up, 16 
patients (2.2%) had withdrawn consent, 103 patients (14.0%) were 
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still being followed up (n = 21 [2.9%] on treatment; n = 82 [11.1%] 
not on treatment), and 554 patients (75.3%) had died.
For 34 of the 736 patients (4.6%), fulvestrant dose was unblinded 
after progression to the study drug.
Eight patients (2.1%) crossed over from fulvestrant 250 mg to 
fulvestrant 500 mg.
Survival Analysis
At the initial data cutoff, 378 of 736 patients (51.4%) had died 
(n = 175 [48.3%] in the fulvestrant 500 mg group; n = 203 [54.3%] 
in the fulvestrant 250 mg group) (Table 1). There was a trend for 
improved OS for patients in the fulvestrant 500 mg group com-
pared with those in the fulvestrant 250 mg group (25.1 months vs 
22.8  months, respectively; hazard ratio (HR)  =  0.84, 95% confi-
dence interval (CI) = 0.69 to 1.03, P = .09 for the unadjusted analy-
sis; HR = 0.81, 95% CI = 0.66 to 1.00, P = .049 for the retrospective 
adjusted analysis) (Table 1; Figure 2A).
At the final survival update, 554 of 736 patients (75.3%) had 
died (n  =  261 [72.1%] in the fulvestrant 500 mg group; n  =  293 
[78.3%] in the fulvestrant 250 mg group) (Table  1). There was 
continued separation of the survival curves for fulvestrant 500 mg 
compared with fulvestrant 250 mg. The median time to death for 
patients in the fulvestrant 500 mg group vs the fulvestrant 250 mg 
group was 26.4 months vs 22.3 months, respectively (HR = 0.81, 
95% CI = 0.69 to 0.96, nominal P = .02 for the unadjusted analy-
sis; HR = 0.79, 95% CI = 0.67 to 0.94, nominal P =  .007 for the 
adjusted analysis) (Table 1; Figure 2B).
No statistically significant interaction was observed between the 
six predefined variables indicated in the Method section and fulves-
trant activity (global interaction test P = .62), indicating that the over-
all treatment effect was consistent across the predefined covariables.
Best Response to First Subsequent Therapy
Information on first subsequent therapies was available for 230 
(63.5%) and 239 (63.9%) patients treated with fulvestrant 500 mg 
or 250 mg, respectively. Best response to subsequent therapy is 
detailed in Table 2. For those randomized patients who had sub-
sequent therapy, response to subsequent therapies was similar 
between treatment groups: 8.3% vs 8.4% of patients had either 
complete response or partial response in the fulvestrant 500 mg vs 
250 mg groups, respectively; 24.8% and 32.2% of patients had sta-
ble disease in the fulvestrant 500 mg vs 250 mg groups, respectively; 
and 33.5% and 28.5% of patients had progressive disease in the 













Not ongoing study treatment at DCO
n = 349
Ongoing in survival follow-up, 
but not on treatment   45
Lost to follow-up   33
Dead at DCO    261
Withdrawn consent  10
Not ongoing study treatment at DCO
n = 366
Ongoing in survival follow-up, 
but not on treatment   37
Lost to follow-up   30
Dead at DCO    293
Withdrawn consent  6
Figure 1. CONSORT diagram. DCO = data cutoff.
Table 1. Summary of overall survival*
Information on overall survival









No. died (%) 175 (48.3) 203 (54.3) 261 (72.1) 293 (78.3)
Median time to death, mo 25.1 22.8 26.4 22.3
Median time to death, d 764 693 805 679
Time to death, mo: 25% percentile 12.2 11.5 11.7 11.5
Time to death, mo: 75% percentile NC 41.7 51.1 41.7
* NC = not calculable.
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Tolerability
A summary of patients with an SAE during the entire treatment 
period (main trial plus follow-up phase) is shown in Table  3. 
During the entire treatment period, a total of 35 (9.7%) and 27 
(7.2%) patients had at least one SAE in the fulvestrant 500 mg 
and fulvestrant 250 mg groups, respectively. SAEs that were caus-
ally related to study treatment were reported for eight (2.2%) 
and four (1.1%) patients, and SAEs with an outcome of death 
were reported for five (1.4%) and seven (1.9%) patients in the 
fulvestrant 500 mg and fulvestrant 250 mg groups, respectively, 
during the entire treatment period. Overall, there were no clini-
cally important differences in the profiles of SAEs between the 



























































Hazard ratio (95% CI)
P
0.84 (0.69 to 1.03)
.09








































































Hazard ratio (95% CI)
P
0.81 (0.69 to 0.96)
.02*
Figure 2. Overall survival from date of randomization. A) Overall survival for when 50% of patients had died. B) Overall survival for when 75% 
of patients had died. Analysis by log-rank test. P values are two-sided. *No adjustments for multiplicity were made. Tick marks indicate censored 
observations. CI = confidence interval. © 2010 American Society of Clinical Oncology. All rights reserved (9).
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Discussion
Preclinical and preliminary clinical data prompted the activation of 
the CONFIRM trial comparing fulvestrant 500 mg with fulvestrant 
250 mg in postmenopausal patients with ER-positive advanced 
breast cancer (1,5,6,10). The PFS analysis (primary study endpoint 
of the CONFIRM trial) demonstrated the superiority of 500 mg 
over 250 mg (9). At the time of the PFS analysis, a first OS analysis 
was also performed, and approximately 50% of events had been 
reported. The OS analysis suggested a numerical trend in favor 
of 500 mg over 250 mg despite the lack of a statistically significant 
difference (9). This observed numerical trend favoring fulvestrant 
500 mg led to a decision by the study Steering Committee to plan 
for a second OS analysis at 75% maturity.
This article reports the results of the final 75% OS analysis and 
suggests that fulvestrant 500 mg is superior to fulvestrant 250 mg, 
with a 19% relative reduction in the risk of death and a 4.1-month 
increase in median OS. However, a limitation of this study is that 
the 75% OS analysis is considered exploratory because it was 
planned after the results of the PFS and 50% OS events analyses 
were available; accordingly, no alpha was retained for this analysis 
Table 2. Best response to subsequent therapy*
Available information on first subsequent therapy
Fulvestrant 500 mg (n = 362) Fulvestrant 250 mg (n = 374)
230 239
Category of subsequent therapy, No.
Radiotherapy 8 8
Endocrine therapy 80 74
Chemotherapy 135 142
HER2 directed 0 1
Unknown/other 3 5
Fulvestrant† 4 9
Best response to subsequent therapy, No. (%)
Complete response 2 (0.9) 0
Partial response 17 (7.4) 20 (8.4)
Stable disease 57 (24.8) 77 (32.2)
Progressive disease 77 (33.5) 68 (28.5)
Not evaluable 77 (33.5) 74 (31.0)
* Subsequent endocrine therapy included: anastrozole, exemestane, letrozole, medroxy progesterone, megestrol acetate, and tamoxifen. HER2 = human epidermal 
growth factor receptor 2.
† Fulvestrant was either given at a dose of 250 mg or the dose was not specified.
Table 3. Summary of patients experiencing SAEs during the treatment period*
Available information on SAEs
No. of patients (%)
Fulvestrant 500 mg (n = 361) Fulvestrant 250 mg (n = 374)
Patients with at least 1 SAE during the whole trial
Any SAE 35 (9.7) 27 (7.2)
Any SAE with outcome other than death† 32 (8.9) 22 (5.9)
Any causally related SAE 8 (2.2) 4 (1.1)
SAEs occurring in >1 patient
Acute myocardial infarction 0 (0) 2 (0.5)
Anemia 3 (0.8) 1 (0.3)
Bronchitis 2 (0.6) 0 (0)
Dyspnea 2 (0.6) 1 (0.3)
Femur fracture 1 (0.3) 2 (0.5)
Hyperglycemia 2 (0.6) 0 (0)
Pneumonia 2 (0.6) 0 (0)
Vomiting 2 (0.6) 1 (0.3)
SAEs with outcome of death, preferred term
Acute myocardial infarction 0 (0) 2 (0.5)
Acute renal failure 0 (0) 1 (0.3)
Aspiration 0 (0) 1 (0.3)
Cardiopulmonary failure 1 (0.3) 0 (0)
Suicide 0 (0) 1 (0.3)
Death, cause unknown 1 (0.3) 0 (0)
Dyspnea 2 (0.6) 0 (0)
Hypertension 0 (0) 1 (0.3)
Intestinal adenocarcinoma 1 (0.3) 0 (0)
Meningitis 0 (0) 1 (0.3)
* SAEs = serious adverse events.
† All patients experiencing an SAE with nonfatal outcome (regardless of whether they later had a fatal SAE).
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and no adjustment for multiplicity was possible. Nevertheless, the 
reported results are consistent with the previously reported PFS 
and 50% OS events results (9).
In the attempt to rule out the hypothesis that the observed dif-
ference in OS in favor of fulvestrant 500 mg was mainly the con-
sequence of an imbalance in subsequent therapies delivered after 
progression on the study drug, an investigation of first subse-
quent therapies after progression on fulvestrant was carried out. 
Information on first subsequent therapies was available for approx-
imately two-thirds (64%) of the study population, with 153 and 165 
patients treated with fulvestrant 500 mg and 250 mg, respectively, 
evaluable for best response. The findings show that there was no 
imbalance in type of first subsequent therapies given after progres-
sion on fulvestrant. Last but not least, the analysis shows that the 
objective response rate and stable disease rate for first subsequent 
therapies are very similar between the two treatment groups. In 
summary, the analysis on first subsequent therapies suggests that 
the observed improvement in OS in favor of the 500 mg dose was 
not due to an imbalance in subsequent treatments delivered after 
progression on fulvestrant.
An additional investigation carried out in this study focused on 
the cross-over rate for patients initially treated with 250 mg. The 
study design did not initially allow for a cross-over after progres-
sion on fulvestrant 250 mg. However, when the PFS results were 
available, the study protocol was amended, and patients on treat-
ment with 250 mg were offered the option to cross over to 500 mg. 
Most patients had already progressed on fulvestrant by the time 
the PFS results were available and the study protocol had been 
amended. Accordingly, fulvestrant dose was unblinded after pro-
gression to the study drug for only 34 of the 736 patients. Twenty-
four patients were eligible for crossover (per protocol amendment), 
but the actual cross-over rate was low, with only eight of 374 
patients (2.1%) receiving fulvestrant 500 mg after prior treatment 
with 250 mg. Considering that there is no clinical evidence on the 
activity of fulvestrant 500 mg in patients pretreated with 250 mg, 
it seems unlikely that the suggested OS benefit of 500 mg over 
250 mg is due to the low cross-over rate in this trial.
With regard to the safety profile, the reported results do not sup-
port any clinically relevant difference either in the rate or causality 
of related SAEs between the two treatment groups. Furthermore, 
the number of SAEs with an outcome of death was very similar 
between the two groups (five events for the 500 mg group vs seven 
events for the 250 mg group). In addition, the 500-mg safety profile 
reported in this article is comparable with the safety profile of the 
same dose observed at the time of the PFS analysis.
The results of this study raise a number of questions that need to 
be addressed in future trials. Is fulvestrant given at the 500 mg dose 
a better option than aromatase inhibitors as a first-line therapy for 
postmenopausal patients with ER-positive advanced breast cancer? 
Results from a phase II randomized trial appear to suggest that this 
might be the case (11,12). A phase III trial (the FALCON trial) is 
currently ongoing (ClinicalTrials.gov identifier: NCT01602380) 
in an attempt to address this question.
A trial recently reported by the Southwest Oncology Group 
(SWOG) has suggested that a poly-endocrine therapy approach, 
consisting of the combination of fulvestrant 250 mg with an aro-
matase inhibitor, is superior to single-agent treatment with the 
same aromatase inhibitor (13). No clinical data on the compari-
son between the poly-endocrine therapy and fulvestrant 500 mg 
are available. Ideally, it would be important to have markers driv-
ing our treatment decisions when a first-line endocrine therapy 
approach has to be started. Unfortunately, no markers are cur-
rently available to support our treatment strategies. Interestingly, 
a subgroup analysis run in the context of the SWOG trial seems 
to suggest that most of the benefit from poly-endocrine therapy is 
observed in patients with no prior exposure to endocrine therapy, 
either in the adjuvant or in the advanced setting (13). This sub-
group analysis might explain the contradictory results reported 
in another poly-endocrine therapy trial (the Fulvestrant and 
Anastrozole Combination Therapy [FACT] trial) whose design 
completely overlaps with the SWOG trial but where a signifi-
cantly higher proportion of patients were previously exposed to 
endocrine therapies (14,15).
Last but not least, our results provide a rationale that if fulves-
trant is to be combined with other nonendocrine agents targeting 
molecular pathways involved in the induction of primary or secondary 
endocrine resistance, then the dose should be 500 mg. Results of the 
Breast Cancer Trials of Oral Everolimus 2 (BOLERO-2) show that 
the combination of an endocrine treatment with a compound target-
ing the PI3K pathway can improve the antitumor activity of single-
agent endocrine therapy (16). Fulvestrant might be an ideal partner 
for future combination studies considering that its unique mechanism 
of action leads to ER downregulation, thus preventing not only the 
ER-mediated transcription of several genes but also the cross-talks 
between cytoplasmic ER and several downstream effectors of molecu-
lar pathways involved in resistance to endocrine therapies (17,18).
In summary, based on the final results of the CONFIRM trial, 
which suggest an OS benefit for fulvestrant 500 mg over 250 mg, 
and taking into account that the previously reported PFS results 
were statistically significantly in favor of fulvestrant 500 mg, we 
believe that whenever treatment with fulvestrant should be initi-
ated, this should be at the dose of 500 mg, according to the same 
schedule of this trial.
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